Bristol-Myers Squibb Company

Release Summary

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

Bristol-Myers Squibb Company